Status:
COMPLETED
Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
Lead Sponsor:
Vejle Hospital
Collaborating Sponsors:
Odense University Hospital
Novartis
Conditions:
Multiple Myeloma
Breast Cancer
Eligibility:
FEMALE
Phase:
PHASE2
Brief Summary
The investigators major aim is to determine whether there is a difference in the retention of zoledronic acid in multiple myeloma patients, compared to patients with breast cancer metastasis to bone. ...
Detailed Description
The clinical benefit from treatment with bisphosphonates has been documented in a large number of clinical studies, and bisphosphonates are now widely used for treatment of pain and prevention of bone...
Eligibility Criteria
Inclusion
- Patients diagnosed with breast cancer and metastases to bone.
- Patients diagnosed with multiple myeloma.
- Patients who are scheduled to receive Zometa.
- Post-menopausal women (at least 10 months since last period).
- Newly diagnosed patients must have clear signs of osteolysis.
Exclusion
- Anti-estrogen treatment.
- Patients given chemotherapy during or less than 7 days before study begin.
- Patients receiving glucocorticoids less than 5 days prior to study begin or during the study period (14 days)
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00760370
Start Date
December 1 2008
End Date
December 1 2011
Last Update
December 7 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Odense University Hospital
Odense, Denmark, 5000
2
Vejle Hospital
Vejle, Denmark, 7100